Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials

Joaquim Mullol, Giorgio Walter Canonica, Martin Wagenmann, Andre Coste, Peter Hellings, Scott Nash, Siddhesh Kamat, Urvi Mujumdar, Jérôme Msihid, Asif H Khan, Shahid Siddiqui, Juby A Jacob-Nara, Yamo Deniz, Paul Rowe
European Respiratory Journal 2021 58: PA2520; DOI: 10.1183/13993003.congress-2021.PA2520
Joaquim Mullol
1Hospital Clínic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jmullolmiret@gmail.com
Giorgio Walter Canonica
2Asthma & Allergy Clinic, Department of Biomedical Sciences, Humanitas University & IRCCS Humanitas Research Hospital, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Wagenmann
3Department of Otorhinolaryngology, Düsseldorf University Hospital (UKD), Düsseldorf, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andre Coste
4Henri Mondor University Hospital of Creteil, Creteil, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Hellings
5Department of Otorhinolaryngology—Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Nash
6Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siddhesh Kamat
6Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Urvi Mujumdar
7Sanofi, Cambridge, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jérôme Msihid
8Sanofi, Chilly-Mazarin, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asif H Khan
8Sanofi, Chilly-Mazarin, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahid Siddiqui
6Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juby A Jacob-Nara
7Sanofi, Cambridge, MA, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yamo Deniz
6Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Rowe
9Sanofi, Bridgewater, NJ, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Background: Chronic rhinosinusitis with nasal polyps is a predominantly type-2 mediated inflammatory disease with high symptom and quality of life burden. Dupilumab significantly improved 22-item Sino-Nasal Outcome Test (SNOT-22) total score vs placebo (PBO) in SINUS-24 and SINUS-52 trials (NCT02912468; NCT02898454).

Objectives: Post hoc analysis of pooled SINUS-24 and SINUS-52 to identify the SNOT-22 items most important to patients (pts), assess the effect of dupilumab on these items, and association with objective disease measures.

Methods: Nasal polyp (NPS) and Lund-Mackay (LMK) scores were assessed in pts with and without improvement at Wk 24 in the SNOT-22 items ranked most important by pts at baseline (BL).

Results: Decreased sense of smell/taste and nasal blockage were the most important SNOT-22 items at BL (cited important by 87% and 82% of pts, respectively). More dupilumab (N=438) vs PBO (N=286) pts improved in these items at Wk 24 (smell/taste: 76.7% vs 30.4%; nasal blockage: 79.5% vs 44.4%). Dupilumab significantly improved NPS and LMK in all pts regardless of improvement in SNOT-22 items, with the greatest treatment effect seen in pts who had an improvement (Table below).

Conclusions: A higher percentage of dupilumab-treated pts improved in symptoms most important to pts (smell/taste; nasal blockage) vs PBO. Improvement in these symptoms signals greater improvement in objective measures (LMK and NPS).

SNOT-22 item improvement (Wk 24)
Least squares mean difference vs PBO (Wk 24)Smell/taste
Yes/no
Nasal blockage
Yes/no
NPS–1.78*/–1.19*–1.90*/–1.01*
LMK–5.77*/–4.26*–6.22*/–3.28*
*P<0.0001 vs PBO
  • Immunology
  • Chronic diseases
  • Rhinitis

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2520.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials
Joaquim Mullol, Giorgio Walter Canonica, Martin Wagenmann, Andre Coste, Peter Hellings, Scott Nash, Siddhesh Kamat, Urvi Mujumdar, Jérôme Msihid, Asif H Khan, Shahid Siddiqui, Juby A Jacob-Nara, Yamo Deniz, Paul Rowe
European Respiratory Journal Sep 2021, 58 (suppl 65) PA2520; DOI: 10.1183/13993003.congress-2021.PA2520

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
SNOT-22 items and association with objective measures in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from SINUS-24 and SINUS-52 trials
Joaquim Mullol, Giorgio Walter Canonica, Martin Wagenmann, Andre Coste, Peter Hellings, Scott Nash, Siddhesh Kamat, Urvi Mujumdar, Jérôme Msihid, Asif H Khan, Shahid Siddiqui, Juby A Jacob-Nara, Yamo Deniz, Paul Rowe
European Respiratory Journal Sep 2021, 58 (suppl 65) PA2520; DOI: 10.1183/13993003.congress-2021.PA2520
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Transcriptomic profiles of eosinophilic asthmatic patients classified according to their atopic status
  • Sex Differences in Severe Asthma
  • Inflammatory phenotypes of severe exacerbation of COPD, a clinico-laboratory characterization
Show more Allergy and immunology

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society